EXHIBIT 99.1
Investor Contact:
Doug Farrell
Vice President, Investor Relations
408-731-5285
Affymetrix Announces Fourth
Quarter Total Revenue of Approximately $100 Million
SANTA CLARA, Calif., Jan 08, 2007
(BUSINESS WIRE) — Affymetrix, Inc. (Nasdaq:AFFX) today
announced that based on preliminary financial data, the Company
expects fourth quarter total revenue of approximately $100
million.
“During the fourth quarter,
we delivered important new products to customers and announced
several exciting commercial agreements,” said Stephen P.A.
Fodor, chairman and chief executive officer. “It was a
quarter of solid performance.”
The Company will release fourth
quarter and year end 2006 operating results after the close of the
market on February 7, 2007. Company management will conduct its
quarterly conference call for fiscal year 2007 at 2:00 p.m. Pacific
Time.
About
Affymetrix
Affymetrix scientists invented
the world’s first high-density microarray in 1989 and began
selling the first commercial microarray in 1994. Since then,
Affymetrix GeneChip(R) technology has become the industry standard
in molecular biology research. Affymetrix technology is used by the
world’s top pharmaceutical, diagnostic and biotechnology
companies as well as leading academic, government and
not-for-profit research institutes. More than 1,400 systems have
been installed around the world and more than 7,000 peer-reviewed
papers have been published using the technology. Affymetrix’
patented photolithographic manufacturing process provides the most
information capacity available today on an array, enabling
researchers to use a
